RARE — Ultragenyx Pharmaceutical Inc. Stock Price, Chart & AI Report

Negative Mar 1, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging securities fraud. The complaint claims the company made false statements about setrusumab's effects on Osteogenesis Imperfecta patients and misrepresented Phase III Orbit study results by failing to disclose risks associated with using uncontrolled Phase II data as benchmarks. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the case.

RARE class action lawsuit securities fraud Ultragenyx Pharmaceutical setrusumab Phase III Orbit study investor harm misleading statements

Sentiment note

The company is the defendant in a securities fraud class action lawsuit alleging false and misleading statements regarding clinical trial data and drug efficacy. The allegations suggest intentional misrepresentation of study results and failure to disclose material risks, which directly harms investor interests.

Negative Feb 26, 2026 • 03:15 UTC GlobeNewswire Inc. • Claimsfiler

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Ultragenyx Pharmaceutical faces a securities class action lawsuit after failing to disclose material information regarding failed Phase 3 clinical trials for setrusumab (UX143) in treating osteogenesis imperfecta. The announcement on December 26, 2025 caused the stock to plummet 42% from $34.19 to $19.72 per share. Investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications.

RARE class action lawsuit securities fraud clinical trial failure stock price decline material information disclosure osteogenesis imperfecta setrusumab

Sentiment note

The company faces securities litigation for failing to disclose material information about failed Phase 3 clinical trials, resulting in a 42% stock price decline and significant shareholder losses. The failed trials and announced expense reductions indicate serious operational and financial challenges.

Negative Feb 19, 2026 • 16:00 UTC GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Ultragenyx Pharmaceutical on behalf of investors who purchased securities between August 3, 2023 and December 26, 2025. The complaint alleges that Ultragenyx made false and misleading statements regarding its drug setrusumab and the Phase III Orbit study results, specifically failing to disclose risks associated with the study's interim analysis benchmarks and the lack of placebo control in Phase II trials.

RARE class action lawsuit securities fraud Ultragenyx Pharmaceutical setrusumab Phase III Orbit study misleading statements investor losses

Sentiment note

The company is the subject of a class action lawsuit alleging material misstatements and omissions regarding clinical trial data and drug efficacy. The allegations suggest deliberate minimization of risks and false impressions about drug effects, which typically results in significant investor losses and reputational damage.

Negative Feb 19, 2026 • 03:15 UTC GlobeNewswire Inc. • Claimsfiler

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Ultragenyx Pharmaceutical faces a securities class action lawsuit after failing to disclose material information regarding failed Phase 3 clinical trials for setrusumab (UX143) in treating osteogenesis imperfecta. The announcement on December 26, 2025 caused the stock to plummet 42% from $34.19 to $19.72 per share. Investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications.

RARE class action lawsuit securities fraud clinical trial failure stock price decline material information disclosure osteogenesis imperfecta setrusumab

Sentiment note

The company faces securities litigation for failing to disclose material information about failed Phase 3 clinical trials, resulting in a 42% stock price decline and significant shareholder losses. The failed trials and announced expense reductions indicate serious operational and financial challenges.

Negative Feb 18, 2026 • 20:55 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Rosen Law Firm is soliciting investors who purchased Ultragenyx Pharmaceutical common stock between August 3, 2023 and December 26, 2025 to join a securities class action lawsuit. The lawsuit alleges that Ultragenyx provided materially false and misleading statements regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta, claiming increased bone density does not correlate to reduced fracture rates as promised. The lead plaintiff deadline is April 6, 2026.

RARE securities class action Ultragenyx Pharmaceutical setrusumab Osteogenesis Imperfecta Phase III trials misleading statements investor losses

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding drug efficacy. Defendants allegedly made false statements about setrusumab's ability to reduce fracture rates while concealing that increased bone density does not correlate to the claimed clinical benefits, causing investors to purchase securities at artificially inflated prices.

Negative Feb 18, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with Phase III trial results and overstated confidence in interim analysis benchmarks based on uncontrolled Phase II data. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the case.

RARE class action lawsuit securities fraud Osteogenesis Imperfecta setrusumab Phase III trial investor harm misleading statements

Sentiment note

The company is the defendant in a securities fraud class action lawsuit alleging false and misleading statements about drug trial results, failure to disclose material risks, and misrepresentation of clinical data reliability. These allegations directly harm investor confidence and shareholder value.

Negative Feb 18, 2026 • 00:06 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm

Class action lawsuits have been filed against Ultragenyx Pharmaceutical and Mereo BioPharma for allegedly misleading investors about Phase III clinical trial results for setrusumab in treating Osteogenesis Imperfecta. Both companies announced on December 29, 2025, that their ORBIT and COSMIC studies failed to meet primary endpoints for reducing annualized fracture rates. Ultragenyx stock fell 42.32% and Mereo's ADS declined 87.7% following the announcements. Lead plaintiff deadlines are set for April 6, 2026.

RARE MREO class action lawsuit clinical trial failure setrusumab Osteogenesis Imperfecta securities fraud misleading statements

Sentiment note

Company faces class action lawsuit alleging material misrepresentation regarding Phase III trial outcomes. Stock declined 42.32% following announcement that ORBIT and COSMIC studies failed to meet primary endpoints for reducing fracture rates despite claims of efficacy.

Negative Feb 15, 2026 • 23:11 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Rosen Law Firm has filed a class action lawsuit against Ultragenyx Pharmaceutical on behalf of investors who purchased common stock between August 3, 2023 and December 26, 2025. The lawsuit alleges that defendants made materially false and misleading statements regarding setrusumab's (UX 143) ability to reduce fracture rates in osteogenesis imperfecta patients, while concealing that increased bone density does not correlate to decreased fracture rates. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is April 6, 2026.

RARE securities class action Ultragenyx Pharmaceutical setrusumab Phase III trials osteogenesis imperfecta investor fraud misleading statements

Sentiment note

The company is the defendant in a securities class action lawsuit alleging material misrepresentation regarding clinical trial results and drug efficacy. Allegations include providing false confidence statements about setrusumab's ability to reduce fracture rates while concealing adverse facts, causing investors to purchase at artificially inflated prices.

Negative Feb 15, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with Phase III trial results and overstated confidence in interim analysis benchmarks based on uncontrolled Phase II data. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the lawsuit, with a lead plaintiff deadline of April 6, 2026.

RARE securities fraud class action lawsuit setrusumab Osteogenesis Imperfecta Phase III trial investor harm misleading statements

Sentiment note

The company is the defendant in a securities fraud class action lawsuit alleging false and misleading statements about drug trial results, failure to disclose material risks, and misrepresentation of clinical trial data integrity. These allegations directly harm investor confidence and shareholder value.

Negative Feb 13, 2026 • 20:00 UTC GlobeNewswire Inc. • Schall Law Firm

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Ultragenyx Pharmaceutical securities between August 3, 2023 and December 26, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its drug candidate's effectiveness for Osteogenesis Imperfecta treatment, with the failure of the Phase III ORBIT study to achieve statistically significant fracture rate reduction revealing the misrepresentations.

RARE securities fraud class action lawsuit Ultragenyx Pharmaceutical Osteogenesis Imperfecta Phase III ORBIT study shareholder litigation misleading statements

Sentiment note

The company is accused of making false and misleading statements about its drug candidate's efficacy, resulting in investor losses. The failure of the Phase III ORBIT study to meet primary endpoints represents a significant setback and validates the fraud allegations.

Negative Feb 13, 2026 • 03:09 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Rosen Law Firm has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased common stock between August 3, 2023 and December 26, 2025. The lawsuit alleges that defendants made false and misleading statements regarding setrusumab's potential, claiming that while the drug increases bone density, this increase does not correlate to decreased fracture rates as management claimed. Investors who wish to serve as lead plaintiff must file by April 6, 2026.

RARE class action lawsuit securities fraud setrusumab bone density Phase III trials investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about its drug setrusumab's efficacy. Investors claim management misrepresented the correlation between bone density increases and fracture rate reduction, resulting in investor damages.

Negative Feb 11, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with Phase III trial results and overstated confidence in interim analysis benchmarks based on uncontrolled Phase II data. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the case, with a lead plaintiff deadline of April 6, 2026.

RARE securities fraud class action lawsuit setrusumab Osteogenesis Imperfecta Phase III trial investor harm misleading statements

Sentiment note

The company is the defendant in a securities fraud class action lawsuit alleging false and misleading statements about drug trial results, failure to disclose material risks, and misrepresentation of clinical trial data integrity. These allegations directly harm investor confidence and shareholder value.